Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: A retrospective evaluation

International Clinical Psychopharmacology

Volumn 22, Issue 2, 2007, Pages 101-105

  Gibson, Aaron P ^a   Lynn Crismon, M ^a,b   Mican, Lisa M ^a,c   Fischer, Charles ^c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^c Austin State Hospital   (United States)

Author keywords

Adolescents; Antipsychotic aripiprazole; Children; Pediatric

Indexed keywords

ARIPIPRAZOLE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CHILD PSYCHIATRY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONDUCT DISORDER; DEPRESSION; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; INTELLECTUAL IMPAIRMENT; MALE; MENTAL DISEASE; MENTAL PATIENT; MOOD DISORDER; NAUSEA AND VOMITING; NURSE; OPPOSITIONAL DEFIANT DISORDER; PERSONALITY DISORDER; PHYSICIAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SCHOOL CHILD; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE; WILCOXON SIGNED RANKS TEST;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CLINICAL TRIALS; FEMALE; HUMANS; INPATIENTS; MALE; MENTAL DISORDERS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846972280     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3280119e0c     Document Type: Article

References (17)

1. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, District of Columbia: American Psychiatric Association.
2. Barzman DH, DelBello MP, Kowatch RA, Gernert B, Fleck DE, Pathak S (2004). The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol 14:593-600.
3. Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Falzone R, et al. (2005). Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectrum 10:141-148.
4. Bowles TM, Levin GM (2003). Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 37:687-694.
5. Casey DE (2001). Barriers to progress - the impact of tolerability problems. Int Clin Psychopharmcol 16 (Suppl 1):S15-S19.
6. Crismon ML, DeLeon A, Miller AL (2003). Aripiprazole: does partial dopaminergic agonism translate into clinical benefits? Ann Pharmacother 37:738-740.
7. DeLeon A, Patel N, Crismon ML (2004). Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
8. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. (2003). Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123-136.
9. Martin A, Scahill L, Anderson GM, et al. (2004). Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125-1127.
10. McConville BJ, Sorter MT (2004). Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 65 (Suppl 6):20-29.
11. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. (2004). A comparison of weight change during treatment with olanzapine or aripipazole: results from a randomized, double-blind study. J Clin Psychiatry 65 (Suppl 18):47-56.
12. Nyilas M, Findling RL, Batterson JR, et al. (2003). Aripiprazole in pediatric conduct disorder: a pilot study. Poster presentation at the 2003 Annual meeting of the American Academy of Child and Adolescent Psychiatry, Miami Beach, Florida, October 2003.
13. Pappadopulos E, Macintyre JC, Crismon ML, Findling RL, Malone RP, Derivan A, et al. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY) Part II. J Am Acad Child Adolesc Psychiatry 42:145-161.
14. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML (2002). Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996-2000. J Child Adolesc Psychopharmacol 12:221-229.
15. Patel NC, Crismon ML, Hoagwood K, Jensen PS (2005). Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharmacol 15:270-284.
16. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, et al. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY) Part I. J Am Acad Child Adolesc Psychiatry 42:132-144.
17. Stigler KA, Posey DJ, McDougal CJ (2004). Aripiprazole for maladaptive behavior in pervasive development disorders. J Child Adolesc Psychopharmacol 14:455-463.